Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is a Healthcare company (Biotechnology) with a market capitalization of $559M. The Maz Rating grades it against the other companies in its sector.
Zevra Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.40, Zevra Therapeutics, Inc. trades at 7.2x trailing earnings, 3.7x sales and 2.3x book value, with an EV/EBITDA of 4.8. Over the last twelve months it generated about $150M of revenue and $77M of net income. It runs a gross margin of 95.2%, an operating margin of 31.5% and a net margin of 52.8%. It shows return on equity of 38.2%, return on invested capital of 14.8% and a free cash flow yield of 6.8%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 5.46. Over the past 52 weeks the share price ranged from $8.01 to $15.04, with a beta of 0.99.
Zevra Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.